Changes in osteopontin and in biomarkers of bone turnover during human endotoxemia

Bone

Volumn 47, Issue 2, 2010, Pages 388-391

  Grimm, Gabriele ^a   Vila, Greisa ^a   Bieglmayer, Christian ^a   Riedl, Michaela ^a   Luger, Anton ^a   Clodi, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bacterial endotoxin; Bone markers; First phase response; Human studies; Osteopontin

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; ESCHERICHIA COLI ENDOTOXIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; OSTEOCALCIN; OSTEOPONTIN; PARATHYROID HORMONE; PLACEBO; COLLAGEN TYPE 1; LIPOPOLYSACCHARIDE; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE;

ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; BONE TURNOVER; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; CROSSOVER PROCEDURE; DRUG EFFICACY; ENDOTHELIUM CELL; ENDOTOXEMIA; EPITHELIUM CELL; HUMAN; HUMAN EXPERIMENT; MALE; OSTEOBLAST; OSTEOCLAST; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; BLOOD; BONE REMODELING; DRUG EFFECTS; TIME; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; BONE REMODELING; COLLAGEN TYPE I; ENDOTOXEMIA; HUMANS; LIPOPOLYSACCHARIDES; MALE; OSTEOPONTIN; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PLACEBOS; PROCOLLAGEN; TIME FACTORS; YOUNG ADULT;

EID: 77955980664     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.04.602     Document Type: Article

References (25)

1. Hadjidakis D.J., Androulakis I.I. Bone remodelling. Ann N Y Acad Sci 2006, 1092:385-396.
2. Zaidi M. Skeletal remodeling in health and disease. Nat Med 2007, 13:791-801.
3. Hardy R., Cooper M.S. Bone loss in inflammatory disorders. J Endocrinol 2009, 201:309-320.
4. Hollander J.M., Mechanick J.I. Bisphosphonates and the metabolic bone disease in the ICU. Curr Opin Clin Nutr Metab Care 2009, 12:190-195.
5. Denhardt D.T., Noda M., O'Regan W., Pavlin D., Berman J.S. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001, 107:1055-1061.
6. Reinholt F.P., Hultenby K., Oldberg A., Heinegard D. Osteopontin-a possible anchor of osteoclast to bone. Proc Natl Acad Sci USA 1990, 87:4473-4475.
7. Watts N.B. Clinical utility of biochemical markers of bone remodeling. Clin Chem 1999, 45:1359-1368.
8. Seibel M.J. Biochemical markers of bone turnover. Part I: biochemistry and variability. Clin Biochem Rev 2005, 26:97-122.
9. Fukumoto S., Martin T.J. Bone as an endocrine organ. Trends Endocrinol Metab 2009, 20:230-236.
10. Bieglmayer C., Kudlacek S. The bone marker plot: an innovative method to assess bone turnover in women. Eur J Clin Invest 2009, 39:230-238.
11. van der Crabben S.N., Blümer R.M., Stegenga M.E., Ackermans M.T., Endert E., Tanck M.W., Serlie M.J., van der Poll T., Sauerwein H.P. Early endotoxemia increases peripheral and hepatic insulin sensitivity in healthy humans. J Clin Endocrinol Metab 2009, 94:463-468.
12. Beishuizen A., Thijs L.G. Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis. J Endotoxin Res 2003, 9:3-24.
13. Van den Berghe G., Van Roosbroeck D., Vanhove P., Wouters P.J., De Pourcq L., Bouillon R. Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab 2003, 88:4623-4632.
14. Vila G., Maier C., Riedl M., Nowotny P., Ludvik B., Luger A., Clodi M. Bacterial endotoxin induces biphasic changes in plasma ghrelin in healthy humans. J Clin Endocrinol Metab 2007, 92:3930-3934.
15. Chen Y., Bieglmayer C., Höcker P., Dettke M. Effect of acute citrate load on markers of bone metabolism in healthy volunteers. Vox Sang Jun 2009, 97:324-329.
16. Clowes J.A., Riggs B.L., Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 2005, 208:207-227.
17. Redlich K., Hayer S., Ricci R., David J.P., Tohidast-Akrad M., Kollias G., Steiner G., Smolen J.S., Wagner E.F., Schett G. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002, 110:1419-1427.
18. Ozaki Y., Ukai T., Yamaguchi M., Yokoyama M., Haro E.R., Yoshimoto M., Kaneko T., Yoshinaga M., Nakamura H., Shiraishi C., Hara Y. Locally administered T cells from mice immunized with lipopolysaccharide (LPS) accelerate LPS-induced bone resorption. Bone 2009, 44:1169-1176.
19. Vanhorebeek I., Van den Berghe G. The neuroendocrine response to critical illness is a dynamic process. Crit Care Clin 2006, 22:1-15.
20. Zou W., Bar-Shavit Z. Dual modulation of osteoclast differentiation by lipopolysaccharide. J Bone Miner Res 2002, 17:1211-1218.
21. Ashkar S., Weber G.F., Panoutsakopoulou V., Sanchirico M.E., Jansson M., Zawaideh S., Rittling S.R., Denhardt D.T., Glimcher M.J., Cantor H. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000, 287:860-864.
22. Guo H., Cai C.Q., Schroeder R.A., Kuo P.C. Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. J Immunol 2001, 166:1079-1086.
23. Mishima R., Takeshima F., Sawai T., Ohba K., Ohnita K., Isomoto H., Omagari K., Mizuta Y., Ozono Y., Kohno S. High plasma osteopontin levels in patients with inflammatory bowel disease. J Clin Gastroenterol 2007, 41:167-172.
24. Vaschetto R., Nicola S., Olivieri C., Boggio E., Piccolella F., Mesturini R., Damnotti F., Colombo D., Navalesi P., Della Corte F., Dianzani U., Chiocchetti A. Serum levels of osteopontin are increased in SIRS and sepsis. Intensive Care Med 2008, 34:2176-2184.
25. Rittling S.R., Chambers A.F. Role of osteopontin in tumour progression. Br J Cancer 2004, 90:1877-1881.